Immune system components involved in CIDP pathophysiology (CIDP immune components)

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired, immune-mediated disorder of the peripheral nervous system characterized by progressive or relapsing motor and sensory deficits (StatPearls, 2023). The pathophysiology involves a complex interplay of cellular and humoral immune mechanisms, including the infiltration of autoreactive T cells and macrophages into peripheral nerves, leading to segmental demyelination (Nature Reviews Neurology, 2019). A subset of patients exhibits specific autoantibodies against nodal and paranodal proteins, such as Neurofascin-155 and Contactin-1, which disrupt nerve conduction (Journal of Neurology, Neurosurgery & Psychiatry, 2019). Therapeutic strategies target these immune components through various means: intravenous immunoglobulins (IVIG) provide immunomodulation, corticosteroids offer broad anti-inflammatory effects, and rituximab targets B-cell populations. Recent advancements have introduced neonatal Fc receptor (FcRn) inhibitors, such as efgartigimod and rozanolixizumab, which specifically lower pathogenic IgG levels by preventing their recycling (The Lancet Neurology, 2023). Understanding these diverse immune components is essential for the development of precision medicine approaches and the identification of biomarkers for treatment response.

Other names

CIDP immune mediatorsCIDP inflammatory factorsChronic inflammatory demyelinating polyradiculoneuropathy pathophysiology

The mechanisms of action for drugs targeting CIDP immune components include the neutralization of autoantibodies and modulation of Fc receptors by intravenous immunoglobulin, broad suppression of T-cell and cytokine activity by corticosteroids, and the depletion of B-cells by monoclonal antibodies like rituximab. Newer approaches involve the inhibition of the neonatal Fc receptor (FcRn) to accelerate the catabolism of pathogenic IgG antibodies and the blockade of the complement cascade (e.g., C5 inhibition) to prevent membrane attack complex-mediated nerve damage.